

## Special Issue

# Role of Autophagy in Cancer Stem Cells and the Tumor Microenvironment: New Frontiers in Cancer Drug Discovery

### Message from the Guest Editors

To date, attempts to target autophagy for cancer therapy have yielded mixed results and uncovered several challenges. For instance, tumor cells can adapt and develop resistance to autophagy inhibition. Targeting autophagy only revealed efficacy in autophagy-addicted cancers. Additionally, the suppression of autophagy was associated with promoting metastasis and tumor recurrence. As such, the evaluation of (hydroxy)chloroquine in clinical trials revealed several key limitations. A growing body of research suggests that autophagy could modulate various novel mechanisms, including tumor immunity and cancer stem cells. This Special Issue aims to publish original research articles or comprehensive reviews focusing on the role of autophagy in therapeutic resistance, cancer stem cell survival, autophagy addiction, and the tumor microenvironment. It will also focus on studies that shed light on new approaches for targeting autophagy and defining novel pharmacological targets to modulate autophagy in cancer.

### Guest Editors

Dr. Yasser Heikal

Prof. Dr. Alakananda Basu

Prof. Dr. Kasper M. Rouschop

### Deadline for manuscript submissions

15 August 2025



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/195153](https://mdpi.com/si/195153)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)